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As Time Goes By
Current Status and Future Directions in the Controversy Over Stenting
Sanjay Kaul, MD, FACC, Prediman K. Shah, MD, FACC, George A. Diamond, MD, FACC
Los Angeles, California
Drug-eluting stents (DES) have dramatically transformed the landscape of interventional cardiology largely on
the basis of empirical evidence showing profound reduction in angiographic and clinical restenosis without any
significant increase in adverse events. Recent data, however, raise questions regarding the increased risk of late
stent thrombosis associated with DES in more complex lesions and higher-risk patients than those evaluated in
the initial clinical trials or Food and Drug Administration-approved indications, the challenge of continuing long-
term antiplatelet therapy, and the danger of early discontinuation of antiplatelet therapy. We herein review the
current status of this controversy, describe the additional evidence needed for its resolution, and offer recom-
mendations for regulatory reform and 3 specific recommendations to encourage evidence-based patient man-
agement: 1) an emphasis on medical therapies with proven long-term benefit; 2) the use of kinetic modeling to
estimate long-term outcomes of therapies based on the available near-term data; and 3) the restructuring of
reimbursement incentives to encourage the use of evidence-based clinical management strategies. (J Am Coll
Cardiol 2007;50:128–37) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.030b
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tIt’s still the same old story
A fight for love and glory
A case of do or die. . .
The fundamental things apply
As time goes by. . .
Herman Hupfeld (1)
rug-eluting stents (DES) have dramatically transformed
he landscape of interventional cardiology largely on the
asis of empirical evidence showing profound reduction in
ngiographic and clinical restenosis without any significant
ncrease in adverse events. The justification for the enor-
ous surfeit of DES use (totaling nearly 6 million patients
lobally to date at a cost of $4 to $5 billion annually) is
ounded on the notion that restenosis—although not a
ajor impediment on survival—importantly impacts on
uality-of-life and the need for repeat revascularization.
estenosis
t has been argued that the clinical benefits of DES relative
o restenosis and target vessel revascularization (TVR) have
een overestimated in clinical trials compared with clinical
ractice (2–4). This might be a consequence of several
actors: 1) the use of thick-strut stents in the former versus
hin-strut stents in the latter; 2) protocol-driven angiogra-
hy mandated in the former, which inflates restenosis rates
rom the Division of Cardiology, Cedars-Sinai Medical Center, and the David
effen School of Medicine, University of California, Los Angeles, California.s
Manuscript received February 12, 2007; revised manuscript received April 16,
007, accepted April 16, 2007.y about 2-fold; and 3) attenuation of restenosis benefit in
igh-risk patients (diabetes, acute coronary syndromes, and
enal failure) and complex lesions (multivessel disease,
rterial bifurcations, left main disease, chronic total occlu-
ions, and vein grafts) that were not evaluated in the pivotal
linical trials but represent 60% of patients undergoing
tenting in clinical practice (2) (Table 1). As a result,
ubstantial uncertainties remain regarding the safety and
ffectiveness of DES in these “real-world” settings:
What is the clinical relevance of angiographic “late loss”?
What is the impact on frequency or severity of angina,
myocardial ischemia, myocardial infarction (MI),
death, or quality-of-life (not objectively assessed in
any trial)?
What about late complications such as “aneurysms”?
tent Thrombosis
nlike restenosis, stent thrombosis is a rare but potentially
ife-threatening complication of coronary stents. In clinical
rials, the cumulative incidence of stent thrombosis with
ES at 9 to 12 months has ranged from 0.5% to 0.7%,
oughly comparable to the incidence with bare-metal stent
BMS) (2,5,6). By contrast, the rate in registries more
epresentative of clinical practice has been reported to be 2-
o 3-fold higher (7–10). In addition, a key difference is that
he temporal pattern with thrombotic events was not infre-
uently observed beyond 12 months (so-called “very late
hrombosis”) with DES but not with BMS (11). Very late
tent thrombosis has been reported to occur at a rate of
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July 10, 2007:128–37 The Controversy Over DES.2%/year in clinical trials (12) and 0.6%/year with broader
se of DES in clinical practice (13). Although rare, stent
hrombosis can result in death in almost one-third to one-half
f cases (7,8,10,14–17) (Table 2). Although several patient-,
esion-, and procedure-related predictors have been identified,
he strongest independent predictor of stent thrombosis seems
o be premature discontinuation of dual antiplatelet therapy
7,8) (Table 3).
Growing concerns about late thrombosis with DES have
otivated an ad hoc change in clinical practice to continue
ual antiplatelet therapy well beyond the 3 to 6 months
ecommended by treatment guidelines (although extension
o 1 year in patients at low bleeding risk is considered
ptional [18]). However, the results of the PREMIER
egistry, in which nearly 1 in 7 patients discontinued
reatment within 30 days of DES (these patients experienc-
ng a 9-fold higher risk of an adverse event), underscore the
hallenge of adherence with such a strategy (19). Moreover,
he long-term use of dual antiplatelet therapy is associated
ith an inherent risk of bleeding (20). These observations
ighlight several questions that warrant further study:
What is the magnitude and time-course of stent throm-
bosis in “real-world” clinical practice?
What are the mechanisms for its genesis?
What are the clinical and pathophysiologic predictors of
risk?
ndications for DES Use
Table 1 Indications for DES Use
1. “On-label” or FDA-approved use
CYPHER Sirolimus-eluting Coronary Stent (5)
For improving coronary luminal diameter in patients with symptomatic
ischemic disease due to discrete de novo lesions in native coronary
arteries
● 30 mm in length
● 2.5–3.5 mm in diameter
● 50%–99% stenosis
TAXUS Express 2 Paclitaxel-Eluting Coronary Stent System (6)
For improving luminal diameter for the treatment of de novo lesions in native
coronary arteries
● 28 mm in length
● 2.5–3.75 mm in diameter
● 50%–99% stenosis
2. “Off-label” or beyond FDA-approved use
Lesion subsets
● Multivessel disease
● Left main disease
● Bifurcation lesions
● Chronic total occlusions (CTO)
● In-stent restenosis (ISR)
● Small vessels (2.5 mm in diameter) or large vessels (3.75 mm in
diameter)
● Long lesions requiring multiple or overlapping stents
● Saphenous vein grafts (SVG)
● Thrombus containing lesions (acute MI)
High-risk patient subsets
● Diabetics
● Renal dysfunction(ES  drug-eluting stent; FDA  Food and Drug Administration; MI  myocardial infarction.What are safe and effective
ways to mitigate or amelio-
rate this risk?
linical Outcomes
Death or MI)
ven though randomized trials
ave consistently shown reduc-
ions in restenosis with DES,
one of these trials was ade-
uately powered to reliably eval-
ate relatively infrequent but
linically relevant end points
uch as death or MI. Key find-
ngs from long-term follow-up of
ajor DES trials were presented
ecently at 2 key meetings, and
hese are summarized in Table 4.
uropean Society of Cardiology/
orld Congress of Cardiology
September 2006)
he current firestorm regarding DES was ignited by the
ndings of 2 group-level meta-analyses first reported at the
uropean Society of Cardiology (ESC)/World Congress of
ardiology (WCC) meeting in Barcelona in September
006. In the meta-analysis reported by Camenzind et al.
21), significantly increased rates of death or Q-wave MI,
resumably due to stent thrombosis, was reported at max-
mum follow-up with sirolimus-eluting stents (SES) (risk
atio 1.60; 95% confidence interval [CI] 1.06 to 2.43) but
ot with paclitaxel-eluting stents (PES) (risk ratio 1.15;
5% CI, 0.79 to 1.69). In a separate meta-analysis of 4
andomized trials, treatment with SES was not associated
ith a difference in total or cardiac mortality at 3 years, but
oncardiac mortality was significantly increased compared
ith BMS (odds ratio 2.04; 95% CI 1.00 to 4.15) (22).
lthough this finding remains largely unexplained, inter-
retations range from a potential (but unlikely) direct
ystemic effect of the small amounts of drug or polymer
eaching from the stent to a subtle influence of redefinition
nd readjudication processes across complex data sets, a
estrictive definition of stent thrombosis requiring confir-
ation on angiography (for which the patient has to be
live) or autopsy (very low prevalence), an uncontrolled
onfounder, or simply a play of chance (23). Similar patterns
ere reported with long-term follow-up of SIRIUS
Sirolimus-Eluting Balloon Expandable Stent in the Treat-
ent of Patients with De Novo Native Coronary Artery
esions), RAVEL (Randomized Study with the Sirolimus-
luting Bx Velocity Balloon-Expandable Stent) (24), and
ASKET (Basel Stent Kosten Effektivitäts Trial) (10)
Table 4). Even though the differences in death or MI were
ot statistically significant in any of the individual trials
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
CAD  coronary artery
disease
CI  confidence interval
CMS  Center for
Medicare and Medicaid
Services
DES  drug-eluting stent(s)
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PES  paclitaxel-eluting
stent(s)
SES  sirolimus-eluting
stent(s)likely owing to inadequate power), the number needed to
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The Controversy Over DES July 10, 2007:128–37arm (NNH) with DES ranged from 12 to 111, and the
robability of any harm (ranging from 69% to 96%) ex-
eeded the probability of any benefit (ranging from 4% to
1%) (Table 4) (25). Although these preliminary estimates
ad not yet been subjected to peer review, they nevertheless
ounded a disquieting alarm, leading to the “demonization”
f DES by the lay media and prompting the U.S. Food and
rug Administration (FDA) to convene a panel of experts
o weigh the risk and benefits of these devices.
he FDA Circulatory System
evices Expert Panel (December 2006)
n open panel meeting of the FDA’s Circulatory System
evices Expert Panel was held in Gaithersburg, Maryland
n December 7 and 8, 2006. Data from a variety of
andomized controlled trials and registries presented to the
anel offered conflicting information about the benefit:risk
atio with DES. On the basis of these findings, the FDA
anel summarized its views regarding so-called “on-label”
se of these devices for approved indications derived from
he pivotal clinical trials and for more widespread “off-label”
se (Table 1) (26).
On-label” use. Both approved DES are associated with a
mall increase in stent thrombosis compared with BMS that
merges 1 year after stent implantation. However, on the
asis of the data available, this increased risk of stent
hrombosis was not associated with an increased risk of
eath or MI compared with BMS.
The concerns about thrombosis do not outweigh the bene-
ts of DES compared with BMS when DES are implanted
ithin the limits of their approved indications for use.
Larger and longer premarket clinical trials and longer
ollow-up for post-approval studies are needed, with uni-
linical Importance of Stent Thrombosis
Table 2 Clinical Importance of Stent Thrombosis
Study Stent Type Confirma
Cutlip et al., 2001 (14) (n  6,186) BMS Angio
Heller et al., 2001 (15) (n  1,855) BMS Angio
Iakovou et al., 2005 (7) (n  2,229) DES Angio
Ong et al., 2005 (16) (n  2,016) DES Angio
Kuchulakanti et al., 2006 (8) (n  2,974) DES Angio
BASKET-LATE, 2006 (10) (n  746) DES Angio
Mauri et al., 2007 (17) (n  4,545) DES Angio
Only MI rates reported; †cardiac death.
BMS  bare-metal stent; DES  drug-eluting stent.
Premature Discontinuation of Clopidogrel Therapy an
Table 3 Premature Discontinuation of Clopidogr
Study
Premature
Yes
Iakovou et al., 2005 (7) 5/17 (29%)
Kuchulakanti et al., 2006 (8) 14/310 (4.5%)
PAR  Pr  [(RR  1)/Pr  (RR  1)  1].
CI  confidence interval; DES  drug-eluting stent; PAR  population att
relative risk.orm definitions of stent thrombosis and close attention
aid to patient compliance with antiplatelet therapy.
Off-label” use. Off-label use of DES is associated with an
ncreased risk of stent thrombosis, death, or MI compared
ith on-label use.
The available data were insufficient to determine whether
he increased risk in adverse events with off-label use was
he same or different between the 2 currently approved
ES.
Data on off-label use are limited, and additional studies
re needed to determine optimal treatments for more
omplex patients. Until more data are available, the DES
abels should state that when DES are used off-label, patient
utcomes might not be the same as the results observed in
he clinical trials conducted to support marketing approval.
uration of antiplatelet therapy. Data from several stud-
es suggest that a longer duration of antiplatelet therapy
han is currently included in the DES labeling might be
eneficial.
The optimal duration of antiplatelet therapy, specifically
lopidogrel, is unknown, and DES thrombosis might still
ccur despite continued therapy.
The labeling for both approved DES should include
eference to the 2005 American College of Cardiology
ACC)/American Heart Association (AHA)/Society of
ardiovascular Angiography and Interventions (SCAI) per-
utaneous coronary intervention (PCI) Practice Guidelines
27), which recommend that patients receive aspirin indef-
nitely plus a minimum of 3 months (for SES) or 6 months
for PES) of clopidogrel, with therapy extended to 12
onths in patients at a low risk of bleeding.
The detailed data presented at the FDA meeting sup-
orting these key judgments were recently published en
f Stent Thrombosis Duration Death Death or MI
or clinical 6 months 21% 70%
plus acute MI 9 months 17% 100%
or clinical 9 months 45% 93%
plus clinical 1 month 25% 100%
6 months 31% 72%*
plus clinical 18 months 19%† 88%†
plus clinical 4 yrs 31% 84%*
k of Stent Thrombosis With DES
rapy and Risk of Stent Thrombosis With DES
ntinuation
RR (95% CI) PARNo
24/2,212 (1.0%) 27 (12, 63) 17%
24/2,658 (0.9%) 5 (3, 10) 29%tion o
gram
gram
gram
gram
gram
gram
gramd Ris
el The
Discoributable risk; Pr  prevalence of clopidogrel discontinuation; RR 
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July 10, 2007:128–37 The Controversy Over DESasse online as a series of articles in the New England
ournal of Medicine (12,17,28–30). A close scrutiny of these
ata offer critical insights and raise additional important
uestions.
ON-LABEL” USE. In contrast to the group-level meta-
nalyses presented by Camenzind et al. (21) and Nordmann
t al. (22) at the ESC/WCC meeting, the results of 3
eta-analyses presented at the FDA meeting were both
ased on individual patient-level data. Examination of the
eta-analysis by Stone et al. (12) suggested a nonsignificant
ncrease in the cumulative 4-year risk of death or Q-wave
I with the SES compared with BMS (hazard ratio 1.30,
5% CI 0.91 to 1.86). In contrast, no excess in death or
-wave MI was reported for PES (12). The meta-analysis
y Kastrati et al. (28) included 14 trials (both pivotal and
ost-marketing trials) and reported virtually no difference
ith respect to mortality (hazard ratio 1.03, 95% CI 0.82 to
.30) and death or MI (hazard ratio 0.97, 95% CI 0.81 to
.16) with SES compared with BMS. Overall, with respect
o death or MI, the probability of any benefit exceeded
robability of any harm with PES and with SES in the
eta-analysis by Kastrati et al. (28) but not in the meta-
ong-Term Follow-Up of “On-Label” Use of DES (Randomized Clinica
Table 4 Long-Term Follow-Up of “On-Label” Use of DES (Rando
Trial End Point F
ESC/WCC, September 2006
Camenzind et al. (21) meta-analysis
SES vs. BMS (n  1,748) (4 trials) Death or Q-wave MI Last
PES vs. BMS (n  3,364) (5 trials) Death or Q-wave MI Last
Nordmann et al. (22) meta-analysis (4 trials)
SES vs. BMS (n  1,748) Death
SES vs. BMS (n  1,748) Noncardiac death
SIRIUS (SES vs. BMS) Death
Death or MI
RAVEL (SES vs. BMS) Death
Death or MI
BASKET (SES or PES vs. BMS) Death or MI
FDA panel, December 2006
Stone et al. (12) meta-analysis
SES vs. BMS (n  1,748) (4 trials) Death
Death or Q-wave MI
ST Da
Late ST
PES vs. BMS (n  3,513) (5 trials) Death
Death or Q-wave MI
ST Da
Late ST
Kastrati et al. (28) meta-analysis
SES vs. BMS (n  4,958) (14 trials) Death
Death or MI
ST Day
Late ST
Numbers needed to treat for benefit are shown in parentheses (NNT or NNH values ranging from
ESC/WCC  European Society of Cardiology/World Congress of Cardiology; F/U  follow up; N
irolimus-eluting stent; ST  stent thromboses; other abbreviations as in Tables 1 and 2.nalysis by Stone et al. (12) (Table 4). Another pooled rnalysis of data from the 4 pivotal SES trials reported that
lthough overall survival and event rates were not signifi-
antly different at 4 years, among diabetic patients (25% of
otal population), use of SES was associated with increased
ccurrence of very late stent thrombosis and almost a
ripling of mortality (hazard ratio 2.9; 95% CI 1.38 to 6.10;
 0.008) (29).
With respect to stent thrombosis, the cumulative inci-
ence of stent thrombosis was numerically greater but not
tatistically significant with both types of DES (12,28,29).
f note, the incidence of very late stent thrombosis (1
ear) was significantly greater with both DES compared
ith BMS. However, despite this increase in stent throm-
osis, risk of death or MI was not significantly increased
ith either DES. A likely explanation might be related to
nsufficient pooled sample size resulting in a  (false-
egative) error of about 60% to 70%. An adequately
owered study would require a sample size 10,000 pa-
ients to permit detection of differences in risk (29).
In an attempt to establish the precise incidence of stent
hrombosis, a new standardized hierarchical definition pro-
osed by Academic Research Consortium (ARC)—a
ls)
Clinical Trials)
-Up
Incidence (%)
p Value
NNH Probability
DES BMS (NNT)* Benefit Harm
3 yrs) 6.3 3.9 0.03 42 1% 99%
3 yrs) 3.3 2.8 0.46 227 23% 77%
4.7 3.1 0.09 66 4% 96%
3.2 1.6 0.04 66 2% 98%
6.0 4.6 0.30 71 15% 85%
8.4 6.7 0.27 58 13% 87%
12.1 7.1 0.26 20 13% 87%
18.9 10.5 0.09 12 4% 96%
o 8.4 7.5 0.63 111 31% 69%
6.7 5.3 0.23 71 11% 89%
8.2 6.4 0.14 56 7% 93%
4 yrs 1.2 0.6 0.20 167 10% 90%
rs 0.6 0.0 0.025 167 1% 99%
6.1 6.6 0.68 (200) 66% 34%
7.3 7.5 0.93 (500) 54% 46%
4 yrs 1.3 0.9 0.30 250 15% 85%
rs 0.7 0.2 0.028 200 1% 99%
rs 5.9 5.9 0.80 1,428 40% 60%
rs 9.7 10.2 0.76 (200) 62% 38%
–5 yrs 1.4 1.2 0.75 500 37% 63%
rs 0.6 0.1 0.02 182 1% 99%
80 are deemed clinically important).
numbers needed to harm; NNT  numbers need to treat; PES  paclitaxel-eluting stent; SES l Tria
mized
ollow
F/U (
F/U (
3 yrs
3 yrs
4 yrs
4 yrs
5 yrs
5 yrs
18 m
4 yrs
4 yrs
y 0 to
1–4 y
4 yrs
4 yrs
y 0 to
1–4 y
1–5 y
1–5 y
0 to 1
1–5 y
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The Controversy Over DES July 10, 2007:128–37egulators—was applied retrospectively to the DES trials
17). Stent thrombosis was classified as definite (angio-
raphic or pathologic confirmation of acute thrombosis in
cute coronary syndromes), probable (any unexplained
eath within 30 days or as target vessel MI without
ngiographic confirmation of thrombosis or other identified
ulprit lesion), or possible (any unexplained death after 30
ays) by the ARC definition (17).
There are several potential limitations of the ARC
efinitions for stent thrombosis: 1) they are derived primar-
ly from the results on the basis of clinical trials with little or
o insights into the risk of stent thrombosis in “real world”
atients; 2) the inclusion of any unexplained death within
0 days as probable stent thrombosis might be biased in
avor of DES, owing to a higher frequency of late throm-
osis (30 days) compared with BMS; 3) the inclusion of
ll unexplained deaths beyond 30 days as possible stent
hromboses might be overly inclusive, because a number of
actors other than stent thrombosis (including natural his-
ory events) might result in an unexplained death, thus
iluting out true stent thrombosis signal; 4) in contrast to
he original protocol-defined criterion, events occurring
fter intervening target lesion revascularization (TLR) (sec-
ndary thrombosis) are not censored in the ARC defini-
ions, thereby introducing confounding due to treatment-
elated complications (for example, brachytherapy used to
reat restenosis is known to predispose to late stent throm-
osis); 5) the ARC definitions have not been vetted by the
rofessional societies, such as the AHA, ACC, and SCAI;
nd 6) the ARC definitions require prospective evaluation
nd validation in ongoing trials.
The results of post hoc re-adjudication of the ARC
efinitions (on the basis of “definite” or “probable” throm-
osis) to pooled data from the pivotal SES trials are shown
n Figures 1A and 1B. Three key observations are worth
oting. First, the majority of death (88% SES [50 of 57] and
8% BMS [35 of 45]) and death or MI (83% SES [83 of
00] and 68% BMS [61 of 89]) were not attributable to
LR or stent thrombosis, suggesting other potential causes
uch as progression of disease in non-culprit lesions or
ncomplete capture of etiology due to lack of angiographic
r autopsy confirmation in all cases. This is consistent with
he observation that stent thrombosis accounted for8% of
verall deaths (21 of 280) and 18% of all MIs (57 of 324)
eported in the pivotal SES and PES trials (17). Second,
eath or MI rate associated with stent thrombosis is 100%
13 of 13 SES, 15 of 15 BMS) compared with about 6%
ith restenosis (4 of 67 SES, 13 of 202 BMS), thereby
onfirming the relatively “benign” nature of the latter
ompared with the former. Third, a nearly significant
ncrease in the rate of death or MI unrelated to stent
hrombosis or TLR (2.5% absolute risk difference) was
bserved with SES that was partially (50%) offset by a
eduction in adverse events associated with TLR (1.0%
bsolute risk difference) (Fig. 1B). This offset would have
een substantially attenuated if events secondary to inter-Figure 1 Pooled Analysis of RAVEL,
SIRIUS, E-SIRIUS, and C-SIRIUS Trials
(A) Data regarding clinically-driven target lesion revascularization (TLR), stent
thrombosis (ST), based on definite or probable cases (as a reliable approximation
of the true incidence of stent thrombosis) according to the Academic Research
Consortium (ARC) definition and includes events post-TLR (secondary thrombosis),
death (D) or myocardial infarction (MI) are shown for sirolimus-eluting stents (SES)
and bare-metal stents (BMS). There were 3 additional cases of stent thrombosis
in the SES and 10 in the BMS group resulting in a total of 13 versus 15 cases
(compared to 10 vs. 5 cases using the protocol-defined criterion). Six out of the
10 additional thrombotic episodes in the BMS group occurred after intervening TLR
(5 related to brachytherapy) compared to none in the SES group. There were a
total of 100 death or MI events in the SES group (11.4%) compared to 89 in the
BMS group (10.2%). (B) Attributable cause of death or myocardial infarction follow-
ing stenting. Differences in the rates of all-cause death or myocardial infarction
(top panel) and all-cause death (bottom panel) between SES (n  878) and BMS
(n  870) attributable to clinically-driven target lesion revascularization (post-TLR),
stent thrombosis (post-ST) based on definite or probable cases according to ARC
definition, and other (non-ST or TLR). Data are shown as relative risk and 95% con-
fidence intervals.
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July 10, 2007:128–37 The Controversy Over DESening TLR (6 BMS vs. 0 SES) were not counted per
rotocol. Furthermore, the notion that reduced risk second-
ry to reduced restenosis might be offset by increased risk
ssociated with late stent thrombosis (12) is not apparent
rom these data. It is also not clear whether the excess deaths
ith SES (57 vs. 45) were cardiac or noncardiac in origin.
n the basis of these observations, several lingering ques-
ions remain:
How and why do the results of individual patient-level
meta-analysis differ from group-level meta-analysis
(commonly reported in published literature and typi-
cally used for formulating treatment guidelines)?
Why is there no significant increase in death or MI with
DES despite increase in late stent thrombosis?
What is the impact of censoring or counting events
(death, MI, or stent thrombosis) related to interven-
ing repeat revascularization?
What is the impact of end point criterion on outcomes
(Q-wave MI vs. non–Q-wave MI, procedural vs.
non-procedural MI)?
What is the mechanism of death (cardiac vs. noncardiac)
or MI after stenting?
What is the optimal measure of overall risk and benefit of
stenting?
What is the temporal relation between stent thrombosis,
death, or MI and discontinuation of clopidogrel
treatment?
OFF-LABEL” USE. Information related to broader clinical
se of DES is primarily derived from uncontrolled registries.
ata from the 7,393-patient ARRIVE registry of “real-
orld” experience with the PES showed that at 2 years the
ajor cardiac events in PES recipients with more complex
esions (including multiple stents) were higher than in PES
ecipients with simple lesions (death: 6.5 vs. 4.6%, p 0.08;
I: 3.6 vs. 2.1%, p  0.0001; stent thrombosis: 3.0 vs.
.4%, p  0.0001) (31). In addition, stent thrombosis rates
hrough 12 months in selected complex patient or lesion
ubsets ranged from 2.9% (acute MI) to 6.3% (insulin-
equiring diabetics) (31). Other registry data from SCAAR
the Swedish Coronary Angiography and Angioplasty Reg-
stry), suggested an overall 18% relative increase in adjusted
ortality with DES (risk ratio 1.18, 95% CI 1.04 to 1.35)
n nearly 20,000 patients (both “on-label” as well as “off-
abel”) followed for 3 years (30). Of note, a 32% relative
ncrease in mortality (presumably related to stent thrombo-
is) was observed between the time of cessation of clopi-
ogrel treatment at 6 months and 3 years, corresponding to
yearly absolute increased risk of 0.5% with DES. A major
imitation inherent in such nonrandomized comparisons is
he confounding due to selection bias and imbalances in
easured and unmeasured prognostic variables. Thus, larger
andomized trials with longer follow-up that include a
road “real-world” population and that evaluate hard clinical eutcomes of death or MI are warranted to inform clinical
ractice.
One observational study of 4,666 stent recipients fol-
owed for 24 months reported that clopidogrel use predicted
he incidence of death and the composite of death or
onfatal MI for patients who received DES but not BMS
32). At 24 months, the absolute difference in death was
.5% lower and the absolute difference in death or MI
presumably related to stent thrombosis) was 4.5% lower for
hose taking clopidogrel. On the basis of these findings, the
dvisory Panel endorsed the ACC/AHA recommendation
hat treatment with aspirin and clopidogrel for up to 1 year
in patients not at high bleeding risk) might be warranted to
itigate the increased risk for late stent thrombosis (27).
owever, clopidogrel use was not randomized and the
esults might be confounded by imbalances in unmeasured
rognostic factors, small sample size, self-reporting of clo-
idogrel use, lack of accounting for bleeding and cost, and
he failure to directly assess the risk of stent thrombosis.
urthermore, registry data in 3,021 patients from Italy and
ermany suggest that discontinuation of clopidogrel ther-
py was an independent predictor of thrombosis within the
rst 6 months but not beyond 6 months (9 of 16 cases of
hrombosis after 6 months occurred while receiving clopi-
ogrel therapy) (33). These findings, along with the obser-
ations that: 1) the majority (71% to 83%) of late stent
hromboses are not attributable to clopidogrel non-
dherence (Table 3), and 2) the wide window of thrombotic
isk—the median time to late stent thrombosis of 55 days
8) to 16 to 18 months (11) after clopidogrel discontinua-
ion—call into question the assertion that extending dual
ntiplatelet therapy to 12 months will mitigate or ameliorate
he risk of stent thrombosis. Thus, the risk-benefit-cost
rofile of dual antiplatelet therapy is not clear enough to
arrant definitive recommendations. Clearly, randomized
linical trials are warranted to confirm these observations
nd to clarify the remaining uncertainties.
he AHA/ACC/SCAI/American
ollege of Surgeons (ACS)/American Dental
ssociation (ADA) Science Advisory (January 2007)
fter the FDA deliberations, a science advisory endorsed by
major professional societies was published in January 2007
34). This advisory stresses the importance of 12 months of
ual antiplatelet therapy after placement of a drug-eluting
tent and educating the patient and healthcare providers
bout hazards of premature discontinuation. It also recom-
ends postponing elective surgery for 1 year and, if surgery
annot be deferred, considering the continuation of aspirin
uring the perioperative period in high-risk patients with
rug-eluting stents. Although these recommendations are
ased on what can most charitably be described as “incon-
lusive” data, they nevertheless do seem to appropriately
ddress the concerns of antiplatelet therapy. However, it
ould be argued that given our limited understanding of the
xact mechanism and incidence of stent thrombosis, our
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The Controversy Over DES July 10, 2007:128–37nability to accurately identify at-risk patients, and the lack
f effective and safe therapies to mitigate this risk, the most
rudent strategy to limit this rare but potentially life-
hreatening complication at the “current” time is a selective,
houghtful, and evidence-based use of DES—at least, until
he next generation of stents that are more pro-healing and
ess or non-thrombogenic become available. Thus, provid-
ng guidance for optimal indications for DES in clinical
ractice should merit equal if not more important and
rgent consideration. In this regard, it might be advisable
hat the medical professional societies should collaborate
ith the regulators, device sponsors, and reimbursing agen-
ies on the development and implementation of new tools
nd programs that not only help mitigate unnecessary risk
ut also promulgate best practice standards. Otherwise, a
otential consequence might be that the prolonged use of
ual antiplatelet therapy might be used inappropriately to
ationalize the overuse of DES (a “band-aid” solution). A
umber of other relevant questions remain unaddressed:
What precedent(s) support the recommendation for
“off-label” use of a drug (clopidogrel use in non-
emergent PCI not being a labeled indication) to
mitigate the adverse effects of similarly “off-label” use
of a device?
What is the definition of “elective” with respect to the
recommendation that such procedures be deferred for
1 year after stenting, and who is responsible for
making the determination (the patient, the cardiolo-
gist, or the surgeon)? Does (arguably elective) stenting
for chronic stable angina trump (arguably non-
elective) knee replacement in an orthopedically dis-
abled patient or renal transplantation in one on
dialysis?
What are the medicolegal consequences of these
recommendations?
he National Heart, Lung, and
lood Institute (NHLBI) Interventional
ardiology Working Group (January 2007)
n January 30, 2007, the NHLBI convened a panel of
epresentatives from academia, industry, and the FDA to
larify its potential role in the debate over DES. The general
ense of the group was that there was no need for a large,
HLBI-sponsored randomized clinical trial at the present
ime but that a number of more basic questions should be
ddressed such as:
What are the frequency, time course, cause, clinical
predictors, and long-term clinical consequences of
restenosis and thrombosis, and can these dynamics be
accurately modeled?
What are the safety and efficacy of the various treatment
alternatives (medical therapy and bypass surgery) in
patients with chronic stable angina and acute coronary
syndromes? fWhat are the kinetics of drug release and vascular healing
in atherosclerotic vessels compared with non-
atherosclerotic vessels?
What are the optimal type, dose, and duration of
antiplatelet therapy?
How should patients requiring premature termination of
antiplatelet therapy for non-elective surgery be man-
aged (“bridging” therapy)?
here Do We Go From Here?
o far, all of this activity has done little more than clarify the
xtent of the debate. On the one hand, advocates of DES
rgue that the available data are sufficient to continue
business as usual” while supporting on-going trials and
linical registries to monitor long-term outcomes as the
echnology continues to mature. On the other hand, critics
rgue that the level of uncertainty is such that use of DES
hould be limited to “on-label” indications until sufficient
vidence of long-term safety and efficacy are available to
esolve the uncertainties. Although both views can be
ustified as prudent and responsible, it will take a long time
or the practical and economic consequences to play out.
ntil then, we recommend a return to epigraphic “funda-
entals” in the form of regulatory reforms summarized in
able 5 (35) and the following evidence-based proposals.
roposal #1: Evidence-Based
edical Management
vidence-based medical therapy is a rational alternative to
tenting, at least in mild to moderate chronic stable angina
nd asymptomatic patients with coronary artery disease
CAD) and evidence of myocardial ischemia on functional
ssessment (comprising the majority of patients undergoing
lective stenting). The theoretical basis for considering
evascularization versus medical therapy in chronic stable
AD can be distilled into one simple motto—palliation
ersus protection. Although restoring flow via revascular-
zation might be protective in acute CAD, evidence so far
ndicates that it is largely palliative in chronic CAD. A
eta-analysis of 11 trials comparing PCI with or without
tenting versus optimal medical therapy demonstrated no
eduction in mortality, an increase in MI, and no increase in
eed for repeat revascularization with PCI (36). These
bservations were recently reinforced by the results of the
OURAGE (Clinical Outcomes Utilizing Revasculariza-
ion and Aggressive Drug Evaluation) trial, which demon-
trated that as an initial management strategy in patients
ith stable CAD, PCI did not reduce the risk of death, MI,
r other major cardiovascular events when added to optimal
edical therapy. Although a small but statistically signifi-
ant improvement in anginal relief was observed in favor of
CI at 1 and 3 years, the differences were no longer
ignificant at 5 years of follow-up (37). However, DES were
ot routinely used in this study. In contrast, disease modi-
ying therapy (life-style changes, aspirin, lipid-lowering,
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July 10, 2007:128–37 The Controversy Over DESeta-blockers, angiotensin-converting enzyme inhibition) is
oth palliative and protective for both acute and chronic
AD.
For avoidance of death or repeat revascularization,
oronary artery bypass graft is a clear winner in some
ubsets (left main, multivessel disease with impaired left
entricular function). For ameliorating symptoms and
mproving quality of life (and perhaps avoidance of
eurocognitive dysfunction), PCI (with or without stent-
ng) might be preferable in patients with severe angina
nd documented ischemia. However, for improving sur-
ival and avoiding MIs without compromising quality of
ife, therapeutic life-style modification and optimal med-
cal therapy might be the most desirable option overall.
hus, medical therapy is a rational and justifiable alter-
ative to stenting unless there is a clear need for
ntervention (acute CAD). Even in these settings, no
lear-cut advantage of DES over BMS is apparent from
ecommended Reforms
Table 5 Recommended Reforms
1. Approval process
Larger and longer pre-approval randomized clinical trials
Broad spectrum of patients representative of clinical practice
Hard clinical endpoints of all cause death or Q-wave myocardial infarction
Adequately powered to address death or Q-wave myocardial infarction
Post-approval device registries with extended follow-up (5–10 yrs) and
greater and timely public access to data
2. Operational standards
Explicit standards of evidence
Robust trial design and statistical methodology
Emphasis on clinical importance  statistical significance
Universal criteria adopted by principal stakeholders
Sponsors, investigators, regulators, reimbursers/payors,
professional/technical societies, guideline committees
3. Administrative reforms
Comprehensive post-marketing surveillance
Accurate, user-friendly, point-of-care, easily trackable, electronic
Resultant labeling changes (if warranted)
Balancing private versus public interests
Encourage innovation without compromising public safety
Incentives to encourage compliance and education
Consistent public policy
“Off-label” use of drug (clopidogrel) to optimize “on-label” use of DES
4. Additional targets
Therapeutic reform
Emphasize medical therapy over revascularization strategy for stable CAD
Tort reform
Change the current standard of evidence from the “community” to
“evidence-based, best clinical practice” standard
Fiscal reform
Reimbursement incentives to encourage optimal utilization
Full reimbursement for “on-label” use
Scaled-down reimbursement for “off-label” use
Reward evidence-based best clinical practice
dapted from Kaul and Diamond (35).
CAD  coronary artery disease; other abbreviations as in Table 2.andomized clinical trials (38,39).roposal #2: Evidence-Based
inetic Modeling of Outcomes
nce inserted, the stent cannot be removed (except through
ather risky surgery). It is a life-long commitment on the
art of the patient. Nevertheless, only relatively short-term
ata (1 to 5 years) are currently available on its safety and
fficacy. In reviewing the available short-term data for
urposes of regulatory approval, the FDA must ultimately
ake its judgments in the absence of direct long-term
mpirical evidence. Conventional wisdom, however, advises
gainst extrapolation of short-term data beyond its imme-
iate time horizon. As one does so, confidence intervals
iden hyperbolically, thereby undermining the precision of
uch predictions. Clinical trials are not well suited to this
ask, because they are inefficient with respect to time and
esource use. We therefore need alternative ways to make
ong-term predictions from near-term data for purposes of
egulatory approval and clinical decision-making.
Kinetic models can serve this purpose (40,41). In contrast
o a conventional statistical regression model, a kinetic
odel quantifies the time-dependent prevalence of alterna-
ive clinical states in terms of an inter-related network of
tate-to-state transitions. The rate of each of these transi-
ions is quantified empirically by a kinetic rate constant or
ransition probability. One such model describing the
athophysiology of atherosclerotic events in terms of the
nter-relation among cellular inflammation, vascular steno-
is, and clinical outcomes has recently been proposed (40),
nd an analogous model based on the putative inter-relation
mong post-stent restenosis, thrombosis, and clinical events
Fig. 2) can be constructed. Such a model can potentially
elp answer a number of specific questions posed by the
HLBI Working Group, such as the projected clinical
mportance of restenosis and thrombosis over 5 to 10 years
f follow-up, the predicted effect of alternative antiplatelet
Figure 2 Schematic of a Kinetic Model of Restenosis,
Thrombosis, and Adverse Events Post-Stenting
The double arrows indicate reversible state-to-state transitions and the single
arrows indicate irreversible transitions. The rate of each transition can be
quantified in terms of an empirical rate constant or transition probability (not
illustrated). Such models can be used to predict the time-dependent preva-
lence of each state over relatively long periods of follow-up.
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The Controversy Over DES July 10, 2007:128–37trategies on these outcomes, and the design requirements
f clinical trials to assess the accuracy of these predictions.
roposal #3: Evidence-Based
eimbursement as the Driver of Quality
urrently, the Center for Medicare and Medicaid Services
CMS) pays for medical procedures deemed by it to be
reasonable and necessary.” This determination is funda-
entally different from that used by the FDA, through
hich drugs and devices are approved in terms of “safety and
fficacy.” As a result, a number of drugs and devices are
paradoxically) reimbursed by CMS without having proven
safety and efficacy”—the frequent off-label use of DES and
lopidogrel being the most immediate examples.
It is generally acknowledged (even by the FDA) that
hysicians can legitimately employ approved drugs and
evices in “off-label” ways. In fact, many consider such use
o be guaranteed under the First Amendment and other
egal precedents (42). But there is no similar guarantee that
ayers need to reimburse such “off-label” use at the same
evel of “on-label” use. Accordingly, CMS could rescale
eimbursement schedules in proportion to the available
vidence of clinical benefit (43), perhaps under the authority
f the National Coverage Determination process (44). One
imple way to begin could be to set reimbursement for
on-label” use at a higher level than that for “off-label”
se—in line with the current emphasis on “pay-for-
erformance” (45).
Evidence-based reimbursement would thereby provide an
ncentive to physicians and industry alike to conduct the
dditional clinical trials documenting the benefit of such
ses. On the basis of such new evidence, manufacturers
ould then petition the FDA for a new “on-label” indica-
ion—at which time CMS could rescale reimbursement
ccordingly. If the FDA and CMS require additional
tatutory authority to implement such reforms, that author-
ty should be obtained through the passage of suitable
ongressional legislation. Only by linking reimbursement
irectly to evidence of clinical benefit can we resolve
urrent—and future—controversies such as that exempli-
ed by DES.
At the very least, it should make for a stentorian shouting
atch!
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